Pfizer buckles under pressure from Trump, delays drug price increases

Pfizer chief executive Ian Read said late Tuesday that his company would delay increasing the prices of dozens of drug products after President Trump publicly berated the firm one day earlier.

The company, in a statement, said the price increases would effectively be postponed at least until the beginning of 2019 “to give the president an opportunity to work on his blueprint to strengthen the healthcare system and provide more access to patients.”

The announcement marked a successful use of the bully pulpit for Trump and a relatively rapid concession by one of the country’s largest companies. Pfizer moved on July 1 to raise the prices on 41 drug products. Trump, on Monday, tweeted that the company should be “ashamed” and vowed an unspecified response.

Pfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. We will respond!

Trump’s threat does not appear to have substantially affected Pfizer’s stock price, but the firm could have decided that it was unwise to risk become a punching bag for Trump. The president has previously accused the pharmaceutical industry of “getting away with murder” and floated the idea of pushing down drug prices through a government-arranged bidding process. He backed down from that threat in May, but he retains the option.

Trump on Tuesday praised Read for his decision to delay the price increases.

Just talked with Pfizer CEO and @SecAzar on our drug pricing blueprint. Pfizer is rolling back price hikes, so American patients don’t pay more. We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!

Pfizer on Monday defended the price increases, saying they would not lead to a net increase in prices for consumers. But by Tuesday, the company’s position changed as it opted to scrap the increases until at least next year.

Trump in May released a 44-page document that contained a list of ideas for lowering drug prices, but it did not contain any concrete actions that the White House would pursue. Still, Trump predicted that it would lead, within weeks, to a major reduction in drug prices. Prices were not reduced.

Republicans have traditionally criticized government intervention in the pricing practices of private companies. But Trump has broken with GOP economic conventions on many issues, including this one.

Trump has not detailed how precisely he plans to proceed.

Pfizer’s immediate decision was much different from the approach Harley-Davidson took recently. The motorcycle manufacturer also drew attacks from Trump by moving forward with a policy that ran afoul of his agenda, announcing that it would move some jobs outside the United States to produce more motorcycles abroad and avoid tariffs on its exports to Europe. Trump threatened to hit Harley with severe taxes and help its rivals, but the firm so far has not wavered in its plan.

Damian PalettaDamian Paletta is White House economic policy reporter for The Washington Post. Before joining The Post, he covered the White House for the Wall Street Journal. Follow